JP2016516043A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016516043A5 JP2016516043A5 JP2016502444A JP2016502444A JP2016516043A5 JP 2016516043 A5 JP2016516043 A5 JP 2016516043A5 JP 2016502444 A JP2016502444 A JP 2016502444A JP 2016502444 A JP2016502444 A JP 2016502444A JP 2016516043 A5 JP2016516043 A5 JP 2016516043A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- compound
- optionally
- compound according
- branched
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 34
- 239000001257 hydrogen Substances 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 125000001072 heteroaryl group Chemical group 0.000 claims 11
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 150000002431 hydrogen Chemical class 0.000 claims 8
- 125000006710 (C2-C12) alkenyl group Chemical group 0.000 claims 7
- 125000006711 (C2-C12) alkynyl group Chemical group 0.000 claims 7
- 125000005843 halogen group Chemical group 0.000 claims 7
- 125000000623 heterocyclic group Chemical group 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 125000004450 alkenylene group Chemical group 0.000 claims 5
- 125000002947 alkylene group Chemical group 0.000 claims 5
- 125000004419 alkynylene group Chemical group 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 125000003107 substituted aryl group Chemical group 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- 102000004157 Hydrolases Human genes 0.000 claims 1
- 108090000604 Hydrolases Proteins 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 claims 1
- 230000001668 ameliorated effect Effects 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- -1 substituted Chemical class 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
- 0 *C(*)(*)N(*)*c1ccccc1 Chemical compound *C(*)(*)N(*)*c1ccccc1 0.000 description 16
- WHELBNUVILHIHT-UHFFFAOYSA-N Cc(cc1)ccc1-c1ncc[o]1 Chemical compound Cc(cc1)ccc1-c1ncc[o]1 WHELBNUVILHIHT-UHFFFAOYSA-N 0.000 description 8
- DXYYSGDWQCSKKO-UHFFFAOYSA-N Cc1nc2ccccc2[s]1 Chemical compound Cc1nc2ccccc2[s]1 DXYYSGDWQCSKKO-UHFFFAOYSA-N 0.000 description 3
- FKWHHXZNCQKLJG-UHFFFAOYSA-N CNCc(cccn1)c1Oc(cc1)ccc1C(O)=O Chemical compound CNCc(cccn1)c1Oc(cc1)ccc1C(O)=O FKWHHXZNCQKLJG-UHFFFAOYSA-N 0.000 description 2
- ALHUXMDEZNLFTA-UHFFFAOYSA-N Cc1nc2ccccc2nc1 Chemical compound Cc1nc2ccccc2nc1 ALHUXMDEZNLFTA-UHFFFAOYSA-N 0.000 description 2
- WGTUMQXQVLOHQE-UHFFFAOYSA-N CCCN(C)Cc1cccnc1Oc(cc1)ccc1C(OCC)=O Chemical compound CCCN(C)Cc1cccnc1Oc(cc1)ccc1C(OCC)=O WGTUMQXQVLOHQE-UHFFFAOYSA-N 0.000 description 1
- VGZHYZHNXNVWHH-UHFFFAOYSA-N CCCNCc(cc1)cnc1-[n]1c(C)c(C(O)=O)nc1 Chemical compound CCCNCc(cc1)cnc1-[n]1c(C)c(C(O)=O)nc1 VGZHYZHNXNVWHH-UHFFFAOYSA-N 0.000 description 1
- QEYUNVXPSOCBAG-UHFFFAOYSA-N CCNCc1cccnc1Oc1cc(C(O)=O)ccc1 Chemical compound CCNCc1cccnc1Oc1cc(C(O)=O)ccc1 QEYUNVXPSOCBAG-UHFFFAOYSA-N 0.000 description 1
- QMBLXRHXCGJOGU-UHFFFAOYSA-N CCc1ccc(CC(O)=O)cc1 Chemical compound CCc1ccc(CC(O)=O)cc1 QMBLXRHXCGJOGU-UHFFFAOYSA-N 0.000 description 1
- BHIQFQYCZIJUIG-UHFFFAOYSA-N CCc1ccc(CC(OC)=O)cc1 Chemical compound CCc1ccc(CC(OC)=O)cc1 BHIQFQYCZIJUIG-UHFFFAOYSA-N 0.000 description 1
- OLPWVSINLQYDIY-UHFFFAOYSA-N CN(C)Cc(cccn1)c1Oc(cc1)ccc1C(O)=O Chemical compound CN(C)Cc(cccn1)c1Oc(cc1)ccc1C(O)=O OLPWVSINLQYDIY-UHFFFAOYSA-N 0.000 description 1
- YMXQNJHJWAVADX-UHFFFAOYSA-N CN(C)Cc1ccc(N(CC2)CCC2C(O)=O)nc1 Chemical compound CN(C)Cc1ccc(N(CC2)CCC2C(O)=O)nc1 YMXQNJHJWAVADX-UHFFFAOYSA-N 0.000 description 1
- JBOVVZBMLVRDAP-UHFFFAOYSA-N CN(CCOC)Cc(cccc1)c1Oc1cccc(C(O)=O)c1 Chemical compound CN(CCOC)Cc(cccc1)c1Oc1cccc(C(O)=O)c1 JBOVVZBMLVRDAP-UHFFFAOYSA-N 0.000 description 1
- LJVIXOQEJPEWJW-UHFFFAOYSA-N CNCc(cc1)cnc1NCCC(O)=O Chemical compound CNCc(cc1)cnc1NCCC(O)=O LJVIXOQEJPEWJW-UHFFFAOYSA-N 0.000 description 1
- YCESUPDCBCISGX-UHFFFAOYSA-N CNCc(cccn1)c1Oc(ccc(C(O)=O)c1)c1OC Chemical compound CNCc(cccn1)c1Oc(ccc(C(O)=O)c1)c1OC YCESUPDCBCISGX-UHFFFAOYSA-N 0.000 description 1
- VYMYSBRLXXKRPA-UHFFFAOYSA-N CNCc1ccc(N(C)CC(O)=O)nc1 Chemical compound CNCc1ccc(N(C)CC(O)=O)nc1 VYMYSBRLXXKRPA-UHFFFAOYSA-N 0.000 description 1
- RPLYIPWVKQPFFL-UHFFFAOYSA-N CNCc1ccc(NCc(cc2)ccc2C(O)=O)nc1 Chemical compound CNCc1ccc(NCc(cc2)ccc2C(O)=O)nc1 RPLYIPWVKQPFFL-UHFFFAOYSA-N 0.000 description 1
- UDOMVKIVDINFMC-UHFFFAOYSA-N COC(c1ccc(CSC)cc1)=O Chemical compound COC(c1ccc(CSC)cc1)=O UDOMVKIVDINFMC-UHFFFAOYSA-N 0.000 description 1
- GHPODDMCSOYWNE-UHFFFAOYSA-N Cc(cc1)cc2c1OCO2 Chemical compound Cc(cc1)cc2c1OCO2 GHPODDMCSOYWNE-UHFFFAOYSA-N 0.000 description 1
- LNJMHEJAYSYZKK-UHFFFAOYSA-N Cc1ncccn1 Chemical compound Cc1ncccn1 LNJMHEJAYSYZKK-UHFFFAOYSA-N 0.000 description 1
- KCTZYAAHUYSVON-UHFFFAOYSA-N OC(c1ccc(CS)cc1)=O Chemical compound OC(c1ccc(CS)cc1)=O KCTZYAAHUYSVON-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361781168P | 2013-03-14 | 2013-03-14 | |
| US61/781,168 | 2013-03-14 | ||
| PCT/US2014/027449 WO2014152536A2 (en) | 2013-03-14 | 2014-03-14 | Inhibitors of leukotriene a4 hydrolase |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016516043A JP2016516043A (ja) | 2016-06-02 |
| JP2016516043A5 true JP2016516043A5 (enExample) | 2017-04-13 |
| JP6562898B2 JP6562898B2 (ja) | 2019-08-21 |
Family
ID=51581719
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502444A Active JP6562898B2 (ja) | 2013-03-14 | 2014-03-14 | ロイコトリエンａ４加水分解酵素の阻害剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9822106B2 (enExample) |
| EP (1) | EP2968265A4 (enExample) |
| JP (1) | JP6562898B2 (enExample) |
| KR (1) | KR20150131211A (enExample) |
| AU (2) | AU2014239585B2 (enExample) |
| BR (1) | BR112015022227A2 (enExample) |
| CA (1) | CA2906086A1 (enExample) |
| MX (1) | MX2015011676A (enExample) |
| RU (1) | RU2690489C2 (enExample) |
| WO (1) | WO2014152536A2 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200730474A (en) | 2005-12-29 | 2007-08-16 | Schering Ag | Diamine derivatives as inhibitors of leukotriene A4 hydrolease |
| RU2686101C2 (ru) | 2013-03-12 | 2019-04-24 | Селтакссис, Инк. | Способы ингибирования лейкотриен- а4-гидролазы |
| EP2970309A4 (en) | 2013-03-14 | 2016-11-09 | Celtaxsys Inc | INHIBITORS OF LEUCOTRIENE A4 HYDROLASE |
| AU2014240042C1 (en) * | 2013-03-14 | 2019-09-05 | Celltaxis, Llc | Inhibitors of leukotriene A4 hydrolase |
| MA52119A (fr) | 2015-10-19 | 2018-08-29 | Ncyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
| PT3377488T (pt) | 2015-11-19 | 2022-11-21 | Incyte Corp | Compostos heterocíclicos como imunomoduladores |
| US12084472B2 (en) | 2015-12-18 | 2024-09-10 | Ardelyx, Inc. | Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists |
| TW202246215A (zh) | 2015-12-18 | 2022-12-01 | 美商亞德利克斯公司 | 作為非全身ｔｇｒ５促效劑之經取代之４－苯基吡啶化合物 |
| SI3394033T1 (sl) | 2015-12-22 | 2021-03-31 | Incyte Corporation | Heterociklične spojine kot imunomodulatorji |
| WO2017192961A1 (en) | 2016-05-06 | 2017-11-09 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| EP3464279B1 (en) | 2016-05-26 | 2021-11-24 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| PL3472167T3 (pl) | 2016-06-20 | 2022-12-19 | Incyte Corporation | Związki heterocykliczne jako immunomodulatory |
| EP3484866B1 (en) | 2016-07-14 | 2022-09-07 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| ES2941716T3 (es) | 2016-08-29 | 2023-05-25 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| JP7174700B2 (ja) * | 2016-12-09 | 2022-11-17 | セルタクシー、エルエルシー | ロイコトリエンａ４ヒドロラーゼの阻害剤としてのモノアミン及びモノアミン誘導体 |
| WO2018119286A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Bicyclic heteroaromatic compounds as immunomodulators |
| MY197501A (en) | 2016-12-22 | 2023-06-19 | Incyte Corp | Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers |
| KR102696516B1 (ko) | 2016-12-22 | 2024-08-22 | 인사이트 코포레이션 | 면역조절제로서의 벤조옥사졸 유도체 |
| US20180179201A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| EP3558973B1 (en) | 2016-12-22 | 2021-09-15 | Incyte Corporation | Pyridine derivatives as immunomodulators |
| WO2019036024A1 (en) | 2017-08-17 | 2019-02-21 | Bristol-Myers Squibb Company | 2- (1,1'-BIPHENYL) -1H-BENZO [D] IMIDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS AGONISTS OF APELIN AND APJ FOR THE TREATMENT OF CARDIOVASCULAR DISEASES |
| US10925851B2 (en) | 2018-03-15 | 2021-02-23 | Regents Of The University Of Minnesota | Use of Tosedostat and related compounds as analgesics |
| EP4212529B1 (en) | 2018-03-30 | 2025-01-29 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| FI4219492T3 (fi) | 2018-05-11 | 2025-02-17 | Incyte Corp | Heterosyklisiä yhdisteitä immunomodulaattoreina |
| EP3801559B1 (en) | 2018-05-31 | 2025-01-01 | Celltaxis, LLC | Method of reducing pulmonary exacerbations in respiratory disease patients |
| CA3150434A1 (en) | 2019-08-09 | 2021-02-18 | Incyte Corporation | Salts of a pd-1/pd-l1 inhibitor |
| AR120109A1 (es) | 2019-09-30 | 2022-02-02 | Incyte Corp | Compuestos de pirido[3,2-d]pirimidina como inmunomoduladores |
| IL292524A (en) | 2019-11-11 | 2022-06-01 | Incyte Corp | Salts and crystalline forms of a pd-1/pd-l1 inhibitor |
| IL299091A (en) | 2020-08-14 | 2023-02-01 | Novartis Ag | Heteroaryl substituted spiropiperidinyl derivatives and their medicinal uses |
| US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
| WO2022099075A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Crystalline form of a pd-1/pd-l1 inhibitor |
| PE20231438A1 (es) | 2020-11-06 | 2023-09-14 | Incyte Corp | Proceso para hacer un inhibidor de pd-1/pd-l1 y sales y formas cristalinas del mismo |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL6815872A (enExample) | 1967-11-22 | 1969-05-27 | ||
| US4582833A (en) | 1984-04-16 | 1986-04-15 | American Cyanamid Company | 2-(substituted-1-piperazinyl)[1,2,4]triazolo[1,5-a]pyrimidines |
| US4576943A (en) | 1984-10-09 | 1986-03-18 | American Cyanamid Company | Pyrazolo[1,5-a]pyrimidines |
| US5308852A (en) | 1992-06-29 | 1994-05-03 | Merck Frosst Canada, Inc. | Heteroarylnaphthalenes as inhibitors of leukotriene biosynthesis |
| US5631401A (en) * | 1994-02-09 | 1997-05-20 | Abbott Laboratories | Inhibitors of protein farnesyltransferase and squalene synthase |
| CA2200981A1 (en) * | 1994-10-04 | 1996-04-11 | Hisashi Takasugi | Urea derivatives and their use as acat-inhibitors |
| US6506876B1 (en) * | 1994-10-11 | 2003-01-14 | G.D. Searle & Co. | LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use |
| ATE223732T1 (de) | 1996-02-13 | 2002-09-15 | Searle & Co | Arzneimittelkombinationen mit immunosuppressiven wirkungen welche cyclooxygenase-2 inhibitoren und leukotrien lta4 hydrase-inhibitoren enthalten |
| US5925654A (en) * | 1997-03-12 | 1999-07-20 | G.D. Searle & Co. | LTA4 , hydrolase inhibitors |
| US6309561B1 (en) | 1997-12-24 | 2001-10-30 | 3M Innovative Properties Company | Liquid crystal compounds having a chiral fluorinated terminal portion |
| US6380203B1 (en) | 1998-01-14 | 2002-04-30 | Merck & Co., Inc. | Angiogenesis inhibitors |
| CA2325587A1 (en) * | 1998-03-25 | 1999-09-30 | Mendi Higgins | Imidazolone anorectic agents: ii. phenyl derivatives |
| GB9815880D0 (en) | 1998-07-21 | 1998-09-16 | Pfizer Ltd | Heterocycles |
| GB9919776D0 (en) | 1998-08-31 | 1999-10-27 | Zeneca Ltd | Compoujnds |
| AR023659A1 (es) | 1998-09-18 | 2002-09-04 | Vertex Pharma | Un compuesto inhibidor de p38, una composicion farmaceutica que lo comprende y el uso de dicha composicion en el tratamiento y prevencion de estados patologicos |
| PL352367A1 (en) * | 1999-05-17 | 2003-08-25 | Novo Nordisk As | Glucagon antagonists/inverse agonists |
| US6699873B1 (en) | 1999-08-04 | 2004-03-02 | Millennium Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
| US6924313B1 (en) * | 1999-09-23 | 2005-08-02 | Pfizer Inc. | Substituted tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity |
| US6800651B2 (en) * | 2000-02-03 | 2004-10-05 | Eli Lilly And Company | Potentiators of glutamate receptors |
| US6451798B2 (en) | 2000-02-22 | 2002-09-17 | Cv Therapeutics, Inc. | Substituted alkyl piperazine derivatives |
| US6552023B2 (en) | 2000-02-22 | 2003-04-22 | Cv Therapeutics, Inc. | Aralkyl substituted piperazine compounds |
| JP2001354657A (ja) | 2000-06-09 | 2001-12-25 | Sds Biotech:Kk | 置換ピペラジン誘導体及び農園芸用殺菌剤 |
| EP1170353B1 (en) | 2000-07-06 | 2005-11-02 | Fuji Photo Film Co., Ltd. | Liquid crystal composition comprising liquid crystal molecules and aligment promoter |
| WO2002064211A1 (en) | 2001-02-09 | 2002-08-22 | Merck & Co., Inc. | Thrombin inhibitors |
| WO2002069901A2 (en) | 2001-03-02 | 2002-09-12 | Merck Frosst Canada & Co. | Cathepsin cysteine protease inhibitors |
| AUPR362001A0 (en) | 2001-03-08 | 2001-04-05 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
| FR2826011B1 (fr) | 2001-06-14 | 2004-12-10 | Oreal | Nouveaux derives de la 7-oxo-dhea et utilisation cosmetique |
| SE0102616D0 (sv) | 2001-07-25 | 2001-07-25 | Astrazeneca Ab | Novel compounds |
| BR0212512A (pt) | 2001-09-14 | 2004-10-26 | Tularik Inc | Composto, composição farmacêutica e métodos para tratar um distúrbio, condição ou doença, elevar os nìveis do colesterol hdl, reduzir os nìveis de triglicerìdeo, tratar diabete, diminuir a resistência à insulina ou diminuir a pressão arterial e modular a ppardelta |
| US20050143372A1 (en) | 2001-10-30 | 2005-06-30 | Shomir Ghosh | Compounds, pharmaceutical compositions and methods of use therefor |
| EP1501514B1 (en) * | 2002-05-03 | 2012-12-19 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| PL212616B1 (pl) * | 2002-09-19 | 2012-10-31 | Lilly Co Eli | Eter diarylowy i kompozycja farmaceutyczna zawierajaca ten eter |
| US7851486B2 (en) | 2002-10-17 | 2010-12-14 | Decode Genetics Ehf. | Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment |
| EP1562973A4 (en) | 2002-10-17 | 2007-01-03 | Decode Genetics Ehf | RECOMMENDATIONS FOR MYOKARDINFARKT |
| WO2005027886A2 (en) | 2003-09-17 | 2005-03-31 | Decode Genetics Ehf. | Methods of preventing or treating recurrence of myocardial infarction |
| US20040198777A1 (en) | 2002-12-20 | 2004-10-07 | Mitokor, Inc. | Ligands of adenine nucleotide translocase (ANT) and compositions and methods related thereto |
| CA2521000A1 (en) | 2003-04-03 | 2004-10-21 | Kyowa Hakko Kogyo Co., Ltd. | Preventive and/or therapeutic agent for neuropathic pain |
| WO2004099164A1 (en) | 2003-05-02 | 2004-11-18 | Rigel Pharmaceuticals, Inc. | Substituted diphenyl isoxazoles, pyrazoles and oxadiazoles useful for treating hcv infection |
| JP2005008581A (ja) | 2003-06-20 | 2005-01-13 | Kissei Pharmaceut Co Ltd | 新規なピラゾロ［１，５−ａ］ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途 |
| JP2007500703A (ja) * | 2003-07-28 | 2007-01-18 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ベンズイミダゾール、ベンズチアゾールおよびベンゾキサゾール誘導体およびｌｔａ４ｈモジュレーターとしてのそれらの使用 |
| EP1669348A4 (en) * | 2003-09-30 | 2009-03-11 | Eisai R&D Man Co Ltd | NEW ANTIPILIC AGENT CONTAINING A HETEROCYCLIC COMPOUND |
| DE10356579A1 (de) | 2003-12-04 | 2005-07-07 | Merck Patent Gmbh | Aminderivate |
| SE0303480D0 (sv) | 2003-12-19 | 2003-12-19 | Biovitrum Ab | Benzofuranes |
| EP1713809B1 (en) | 2004-02-04 | 2009-07-29 | Neurosearch A/S | Dimeric azacyclic compounds and their use |
| WO2006033795A2 (en) | 2004-09-17 | 2006-03-30 | Wyeth | Substituted pyrazolo [1, 5-a] pyrimidines for inhibiting abnormal cell growth |
| CN101189012A (zh) * | 2005-03-31 | 2008-05-28 | 詹森药业有限公司 | 苯基和吡啶基lta4h调节剂 |
| CA2605985A1 (en) * | 2005-05-03 | 2006-11-09 | Pfizer Inc. | Amide resorcinol compounds |
| CN101184753A (zh) * | 2005-05-31 | 2008-05-21 | 阿斯利康(瑞典)有限公司 | 新颖的mchr1拮抗剂以及它们用于治疗mchr1介导的病症和疾病的用途 |
| GB0514018D0 (en) | 2005-07-07 | 2005-08-17 | Ionix Pharmaceuticals Ltd | Chemical compounds |
| NZ566788A (en) | 2005-09-21 | 2012-10-26 | Decode Genetics Ehf | Biaryl substituted heterocycle inhibitors of LTA4H for treating inflammation |
| CN1947717B (zh) | 2005-10-14 | 2012-09-26 | 卓敏 | 选择性抑制腺苷酸环化酶1的化合物在制备用于治疗神经性疼痛和炎性疼痛的药物中的应用 |
| DE102005049954A1 (de) | 2005-10-19 | 2007-05-31 | Sanofi-Aventis Deutschland Gmbh | Triazolopyridin-derivate als Inhibitoren von Lipasen und Phospholipasen |
| TW200730474A (en) | 2005-12-29 | 2007-08-16 | Schering Ag | Diamine derivatives as inhibitors of leukotriene A4 hydrolease |
| US7820821B2 (en) | 2006-02-10 | 2010-10-26 | Transtech Pharma, Inc. | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors |
| EP1878730A1 (en) * | 2006-07-12 | 2008-01-16 | Bayer Schering Pharma Aktiengesellschaft | Substituted isoxazolines, pharmaceutical compositions containing the same, methods of preparing the same, and uses of the same |
| EP2058309A4 (en) | 2006-08-04 | 2010-12-22 | Takeda Pharmaceutical | CONDENSED HETEROCYCLIC COMPOUND |
| DE602007005671D1 (de) | 2006-10-19 | 2010-05-12 | Hoffmann La Roche | Aminomethyl-2-imidazole mit affinität zu mit dem trace-amin assoziierten rezeptoren |
| SI2121636T1 (sl) | 2006-12-14 | 2017-06-30 | Janssen Pharmaceutica N.V. | Postopek za pripravo derivatov piperazinila in diazepanil benzamida |
| FR2911138B1 (fr) | 2007-01-05 | 2009-02-20 | Sanofi Aventis Sa | Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk |
| FR2911139A1 (fr) | 2007-01-05 | 2008-07-11 | Sanofi Aventis Sa | Nouveaux derives de phenyl-(4-phenyl-pyrimidin-2-yl)amines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk |
| FR2911140B1 (fr) | 2007-01-05 | 2009-02-20 | Sanofi Aventis Sa | Nouveaux derives de 2-anilino 4-heteroaryle pyrimides, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk |
| CN101687844B (zh) | 2007-07-02 | 2013-11-13 | 弗·哈夫曼-拉罗切有限公司 | 用作ccr2受体拮抗剂的咪唑衍生物 |
| JP5341084B2 (ja) * | 2007-08-03 | 2013-11-13 | エフ．ホフマン−ラ ロシュ アーゲー | Ｔａａｒ１リガンドとしてのピリジンカルボキシアミド及びベンズアミド誘導体 |
| WO2009074829A1 (en) | 2007-12-12 | 2009-06-18 | Astrazeneca Ab | Peptidyl nitriles and use thereof as dipeptidyl peptidase i inhibitors |
| FR2928070A1 (fr) * | 2008-02-27 | 2009-09-04 | Sumitomo Chemical Co | Composition agricole, utilisation d'un compose pour sa production et procede pour matriser ou prevenir les maladies des plantes. |
| US20100029657A1 (en) | 2008-02-29 | 2010-02-04 | Wyeth | Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof |
| PT2336125E (pt) * | 2008-04-11 | 2013-03-18 | Janssen Pharmaceutica Nv | Tiazolopiridina-2-iloxi-fenil e tiazolopirazin-2-iloxifenil aminas como moduladores de leucotrieno a4 hidrolase |
| EP2110374A1 (en) | 2008-04-18 | 2009-10-21 | Merck Sante | Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators |
| WO2010011912A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Trpv4 antagonists |
| CN102030700B (zh) * | 2009-09-30 | 2016-06-01 | 中国医学科学院药物研究所 | 苯甲酰胺基羧酸类化合物及其制法和药物用途 |
| EP2509982A1 (en) | 2009-12-07 | 2012-10-17 | Targacept, Inc. | 3,6-diazabicyclo[3.1.1]heptanes as neuronal nicotinic acetylcholine receptor ligands |
| JP2013047189A (ja) * | 2009-12-25 | 2013-03-07 | Kyorin Pharmaceutical Co Ltd | 新規パラバン酸誘導体及びそれらを有効成分とする医薬 |
| CA2806341C (en) | 2010-07-29 | 2020-03-24 | Rigel Pharmaceuticals, Inc. | Ampk-activating heterocyclic compounds and methods for using the same |
| TR201802550T4 (tr) * | 2011-03-14 | 2018-03-21 | Boehringer Ingelheim Int | Lökotrien üretiminin benzodioksan inhibitörleri. |
| WO2012125832A2 (en) | 2011-03-15 | 2012-09-20 | Rib-X Pharmaceuticals, Inc. | Antimicrobial agents |
| CA2837079A1 (en) | 2011-05-23 | 2012-11-29 | Janssen Pharmaceutica Nv | Picolinamido-propanoic acid derivatives useful as glucagon receptor antagonists |
| US9006235B2 (en) | 2012-03-06 | 2015-04-14 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| RU2686101C2 (ru) | 2013-03-12 | 2019-04-24 | Селтакссис, Инк. | Способы ингибирования лейкотриен- а4-гидролазы |
| EP2970309A4 (en) | 2013-03-14 | 2016-11-09 | Celtaxsys Inc | INHIBITORS OF LEUCOTRIENE A4 HYDROLASE |
| AU2014240042C1 (en) | 2013-03-14 | 2019-09-05 | Celltaxis, Llc | Inhibitors of leukotriene A4 hydrolase |
-
2014
- 2014-03-14 JP JP2016502444A patent/JP6562898B2/ja active Active
- 2014-03-14 AU AU2014239585A patent/AU2014239585B2/en not_active Ceased
- 2014-03-14 MX MX2015011676A patent/MX2015011676A/es unknown
- 2014-03-14 KR KR1020157028770A patent/KR20150131211A/ko not_active Ceased
- 2014-03-14 CA CA2906086A patent/CA2906086A1/en not_active Abandoned
- 2014-03-14 WO PCT/US2014/027449 patent/WO2014152536A2/en not_active Ceased
- 2014-03-14 EP EP14769620.7A patent/EP2968265A4/en not_active Withdrawn
- 2014-03-14 BR BR112015022227A patent/BR112015022227A2/pt not_active Application Discontinuation
- 2014-03-14 RU RU2015137977A patent/RU2690489C2/ru not_active IP Right Cessation
-
2015
- 2015-09-10 US US14/849,829 patent/US9822106B2/en active Active
-
2017
- 2017-11-02 US US15/801,494 patent/US20180118735A1/en not_active Abandoned
-
2019
- 2019-07-02 AU AU2019204753A patent/AU2019204753A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016516043A5 (enExample) | ||
| JP2016513696A5 (enExample) | ||
| JP2016513681A5 (enExample) | ||
| JP2016506962A5 (enExample) | ||
| JP2015522650A5 (enExample) | ||
| JP2014503574A5 (enExample) | ||
| JP2015520769A5 (enExample) | ||
| JP2016506961A5 (enExample) | ||
| JP2013542261A5 (enExample) | ||
| JP2019501125A5 (enExample) | ||
| JP2011513305A5 (enExample) | ||
| JP2015537020A5 (enExample) | ||
| JP2014506907A5 (enExample) | ||
| JP2016526576A5 (enExample) | ||
| JP2017509586A5 (enExample) | ||
| JP2014506599A5 (enExample) | ||
| JP2013512903A5 (enExample) | ||
| RU2015146957A (ru) | Производные доластатина 10 и ауристатинов | |
| JP2015500887A5 (enExample) | ||
| JP2017508782A5 (enExample) | ||
| MX336505B (es) | Metodos y composiciones para reducir la grasa y los adipocitos del cuerpo. | |
| EA201391486A1 (ru) | Способы и композиции для лечения болезни паркинсона | |
| JP2017526677A5 (enExample) | ||
| JP2014508804A5 (enExample) | ||
| JP2018527295A5 (enExample) |